Literature DB >> 3579500

The Longitudinal Interval Follow-up Evaluation. A comprehensive method for assessing outcome in prospective longitudinal studies.

M B Keller, P W Lavori, B Friedman, E Nielsen, J Endicott, P McDonald-Scott, N C Andreasen.   

Abstract

The Longitudinal Interval Follow-up Evaluation (LIFE) is an integrated system for assessing the longitudinal course of psychiatric disorders. It consists of a semistructured interview, an Instruction booklet, a coding sheet, and a set of training materials. An interviewer uses the LIFE to collect detailed psychosocial, psychopathologic, and treatment information for a six-month follow-up interval. The weekly psychopathology measures ("psychiatric status ratings") are ordinal symptom-based scales with categories defined to match the levels of symptoms used in the Research Diagnostic Criteria. The ratings provide a separate, concurrent record of the course of each disorder initially diagnosed in patients or developing during the follow-up. Any DSM-III or Research Diagnostic Criteria disorder can be rated with the LIFE, and any length or number of follow-up intervals can be accommodated. The psychosocial and treatment information is recorded so that these data can be linked temporally to the psychiatric status ratings.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3579500     DOI: 10.1001/archpsyc.1987.01800180050009

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  529 in total

Review 1.  A review of the health-related quality of life literature in bipolar disorder.

Authors:  M A Namjoshi; D P Buesching
Journal:  Qual Life Res       Date:  2001       Impact factor: 4.147

2.  Early intervention for youth at high risk for bipolar disorder: A multisite randomized trial of family-focused treatment.

Authors:  David J Miklowitz; Christopher D Schneck; Patricia D Walshaw; Amy S Garrett; Manpreet K Singh; Catherine A Sugar; Kiki D Chang
Journal:  Early Interv Psychiatry       Date:  2017-08-04       Impact factor: 2.732

3.  A prospective study of stress autonomy versus stress sensitization in adolescents at varied risk for depression.

Authors:  Matthew C Morris; Jeffrey A Ciesla; Judy Garber
Journal:  J Abnorm Psychol       Date:  2010-05

Review 4.  An overview of mood disorders in the DSM-5.

Authors:  Jan Fawcett
Journal:  Curr Psychiatry Rep       Date:  2010-12       Impact factor: 5.285

Review 5.  Stability and course of personality disorders: the need to consider comorbidities and continuities between axis I psychiatric disorders and axis II personality disorders.

Authors:  C M Grilo; T H McGlashan; A E Skodol
Journal:  Psychiatr Q       Date:  2000

6.  Patient learning of treatment contents in cognitive therapy.

Authors:  Nicole B Gumport; Lu Dong; Jason Y Lee; Allison G Harvey
Journal:  J Behav Ther Exp Psychiatry       Date:  2017-08-31

7.  Three-pronged assessment and diagnosis of personality disorder and its consequences: personality functioning, pathological traits, and psychosocial disability.

Authors:  Lee Anna Clark; Eunyoe Ro
Journal:  Personal Disord       Date:  2014-01

8.  Risk of suicidal behavior with antidepressants in bipolar and unipolar disorders.

Authors:  Andrew C Leon; Jess G Fiedorowicz; David A Solomon; Chunshan Li; William H Coryell; Jean Endicott; Jan Fawcett; Martin B Keller
Journal:  J Clin Psychiatry       Date:  2014-07       Impact factor: 4.384

9.  Mindfulness-Based Cognitive Therapy for Perinatal Women with Depression or Bipolar Spectrum Disorder.

Authors:  David J Miklowitz; Randye J Semple; Monika Hauser; Dana Elkun; Marc J Weintraub; Sona Dimidjian
Journal:  Cognit Ther Res       Date:  2015-04-21

10.  Two-year stability and change of schizotypal, borderline, avoidant, and obsessive-compulsive personality disorders.

Authors:  Carlos M Grilo; Charles A Sanislow; John G Gunderson; Maria E Pagano; Shirley Yen; Mary C Zanarini; M Tracie Shea; Andrew E Skodol; Robert L Stout; Leslie C Morey; Thomas H McGlashan
Journal:  J Consult Clin Psychol       Date:  2004-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.